These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23855951)

  • 21. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perioperative Management of a Patient With an Intrathecal Drug Delivery Device Infusing Ziconotide: A Case Report.
    Patel S; Hafez O; Sexton WJ; Edwards DA
    A A Case Rep; 2017 Feb; 8(4):78-80. PubMed ID: 28195861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Experience in treatment of patients with neuropathic facial pain using ziconotide].
    Lux EA; Rasche D
    Schmerz; 2011 Aug; 25(4):434-9. PubMed ID: 21818721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ziconotide: an update and review.
    Williams JA; Day M; Heavner JE
    Expert Opin Pharmacother; 2008 Jun; 9(9):1575-83. PubMed ID: 18518786
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
    Wallace MS
    Expert Rev Neurother; 2006 Oct; 6(10):1423-8. PubMed ID: 17078783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trigeminal neuralgia relief with intrathecal ziconotide.
    Michiels WB; McGlthlen GL; Platt BJ; Grigsby EJ
    Clin J Pain; 2011 May; 27(4):352-4. PubMed ID: 21494183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature.
    Webster LR
    Pain Med; 2015 Jul; 16(7):1265-77. PubMed ID: 25645109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class.
    Skov MJ; Beck JC; de Kater AW; Shopp GM
    Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute rhabdomyolysis in a patient with long-term exposure to intrathecal ziconotide: a case report.
    Horazeck C; Huh AS; Huh BK
    Pain Pract; 2015 Mar; 15(3):E34-9. PubMed ID: 25565390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ziconotide-Induced Oro-lingual Dyskinesia: 3 Cases.
    Grajny K; Durphy J; Adam O; Azher S; Gupta M; Molho E
    Tremor Other Hyperkinet Mov (N Y); 2020 Oct; 10():37. PubMed ID: 33101763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intrathecal Ziconotide: Dosing and Administration Strategies in Patients With Refractory Chronic Pain.
    McDowell GC; Pope JE
    Neuromodulation; 2016 Jul; 19(5):522-32. PubMed ID: 26856969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for Prospective Assays of Intrathecal Mixtures Including Morphine, Ropivacaine and Ziconotide: Prevention of Adverse Events and Feasibility in Clinical Practice.
    Dupoiron D; Devys C; Bazin C; Folliard C; Lebrec N; Boré F; Dubois PY; Kieffer H
    Pain Physician; 2015; 18(4):349-57. PubMed ID: 26218938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statistical evaluation of the chemical stability of ziconotide solutions during simulated intrathecal administration.
    Shields DE; Liu W; Gunning K; Montenegro R
    J Pain Symptom Manage; 2008 Jul; 36(1):e4-6. PubMed ID: 18538975
    [No Abstract]   [Full Text] [Related]  

  • 37. CNSB004 (Leconotide) causes antihyperalgesia without side effects when given intravenously: a comparison with ziconotide in a rat model of diabetic neuropathic pain.
    Kolosov A; Goodchild CS; Cooke I
    Pain Med; 2010 Feb; 11(2):262-73. PubMed ID: 20002322
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Administering ziconotide and monitoring patients treated with ziconotide: expert opinions.
    Mitchell AA; Sapienza-Crawford AJ; Hanley KL; Lokey KJ; Wells L; McDowell GC; Stanton-Hicks M
    Pain Manag Nurs; 2013 Sep; 14(3):e84-94. PubMed ID: 23972874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Ziconotide: an innovative alternative for intense chronic neuropathic pain].
    Valía-Vera JC; Villanueva VL; Asensio-Samper JM; López-Alarcón MD; de Andrés JA
    Rev Neurol; 2007 Dec 1-15; 45(11):665-9. PubMed ID: 18050098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A safety review of approved intrathecal analgesics for chronic pain management.
    Chalil A; Staudt MD; Harland TA; Leimer EM; Bhullar R; Argoff CE
    Expert Opin Drug Saf; 2021 Apr; 20(4):439-451. PubMed ID: 33583318
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.